Status:
COMPLETED
STRATEGY for Left Main Coronary Bifurcation Lesion II
Lead Sponsor:
Samsung Medical Center
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
In patients with unprotected left main (LM) true bifurcation lesion (cohort A), elective 2-stent strategy is superior to provisional strategy at preventing the occurrence of 12-month target lesion fai...
Eligibility Criteria
Inclusion
- Age ≥20 years
- Left main bifurcation lesion on coronary angiography
- Significant myocardial ischemia Main vessel (left main coronary artery and left anterior descending artery) and/or side branch (left circumflex artery) diameter stenosis \> 75%, or diameter stenosis 50-75% with angina and/or objective evidence of ischemia in the non-invasive stress test
- Significant size of the main branch (left anterior descending artery) and side branch (left cirmflex artery) - The reference diameter of both branches ≥ 2.5 mm by visual estimation
Exclusion
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Biolimus
- Patients who have received DES implantation in the target lesion prior to enrollment
Key Trial Info
Start Date :
March 18 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01798433
Start Date
March 18 2013
End Date
July 31 2018
Last Update
January 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710